Novo's top US exec wants more insurance coverage for weight-loss drugs

Novo Nordisk said it wants broader U.S. insurance coverage for Wegovy users to help balance its direct-to-consumer sales model. The comment signals an effort to expand access and diversify how the weight-loss drug is distributed, supporting demand visibility. The update is incremental but constructive for the company’s U.S. growth outlook.

Analysis

Novo Nordisk said it wants broader U.S. insurance coverage for Wegovy users to help balance its direct-to-consumer sales model. The comment signals an effort to expand access and diversify how the weight-loss drug is distributed, supporting demand visibility. The update is incremental but constructive for the company’s U.S. growth outlook.